

Laboratoires INNOTHERA

[View the current Laboratoires INNOTHERA Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/24621-Laboratoires+INNOTHERA.html)

(<http://www.bioportfolio.com/biocorporate/24621-Laboratoires+INNOTHERA.html>)

Contact Details:

7-9, avenue François-Vincent Raspail BP 35
Arcueil Cedex

Tel: 01 46 15 18 00

Fax: 01 46 15 19 19

Email: webmaster@innothera.com, soit

94111

France

INNOTHERA est un groupe indépendant, en pleine mutation, implanté en France, avec de fortes perspectives de développement international.

En 1989, le groupe INNOTHERA prend son premier virage stratégique en se recentrant sur la santé des femmes.

En 1999, le groupe INNOTHERA décide de se spécialiser sur la maladie veineuse et de devenir le leader dans le traitement des maladies veineuses.

La maladie veineuse est un véritable problème de santé publique. Grâce aux données issues de l'étude SU.VI.MAX et publiées en 1999, on sait maintenant que 14,6% des hommes et 33,6% des femmes sont touchés par la maladie veineuse chronique, en France. La prévalence des varices augmente avec l'âge et à partir de 55 ans, près de 30% des sujets féminins en sont porteurs. Les phlébotoniques et la contention sont deux des voies de traitement actuelles de cette maladie.

Recent Publications by Laboratoires INNOTHERA:



- [Human muscle fatigue and elastic compressive stockings.](#)
*The present study was performed to test if elastic compressive stockings...*23rd September, 2006
Laboratoires INNOTHERA Service de Biophysique, 7-9 Avenue Francois Vincent- Eur J Appl Physiol.
2006 Jul;97(4):432-42. Epub 2006 May 10. ([DOI Direct Link](#))
- [The venous return simulator: an effective tool for investigating the effects of external compression on the venous hemodynamics--first results after thigh compression.](#)
*BACKGROUND: To present a virtual model, the venous return simulator (VRS),...*30th September, 2005
Service de Biophysique, Laboratoires Innothera, Arcueil, France.- Vasa. 2005 Feb;34(1):19-23.
- [Application of validated ultrasound indices to investigate erythrocyte aggregation in pigs. Preliminary in](#)

[vivo results.](#)

*Although some studies concerning the ultrasound (US) characterization of...*4th June, 2004

Laboratoires- *Ultrasound Med Biol.* 2004 Jan;30(1):35-44. ([DOI Direct Link](#))

- [Comparison of new ultrasound index with laser reference and viscosity indexes for erythrocyte aggregation quantification.](#)

*We have previously established new ultrasonic indexes for erythrocyte...*8th October, 2003

Laboratoires- *Ultrasound Med Biol.* 2003 Jun;29(6):789-99.

Press Releases on Laboratoires INNOTHERA:

Reportlinker Adds Allergan Inc.: PharmaVitae Profile	16th October, 2009	Reportlinker	<i>NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Allergan Inc.: PharmaVitae Profile http://www</i>
ResMed Acquires Laboratoires Narval	5th October, 2009		<i>SAN DIEGO, October 5 /PRNewswire/ -- ResMed Inc. (NYSE: RMD), a leading developer, manufacturer and distributor of sleep and respiratory medical equipment, announced today that it has acquired</i>
Positive CHMP Opinion for JAVLOR(R) in Metastatic Treatment of Bladder Cancer After Failure of a Prior Platinum-Containing Regimen	26th June, 2009	Pierre Fabre SA	<i>CASTRES, France, June 26 /PRNewswire/ -- Laboratoires Pierre Fabre announce today that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European</i>
Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results	23rd April, 2009	Pharmacyclics, Inc.	<i>The Recurring Operational Expense For The Quarter Was \$4.9 Million SUNNYVALE, Calif., April 23 /PRNewswire-FirstCall/ --</i>
Pierre Fabre Donates the Majority Equity Interest in his Company to his Foundation and Appoints Jean-Pierre Garnier General Manager of Pierre Fabre SA	5th September, 2008	Pierre Fabre SA	<i>PARIS, September 5 /PRNewswire/ -- Faithful to the commitment made in 2005 to his employees, Mr. Pierre Fabre asked the Pierre Fabre Foundation's board of directors to accept the donation of</i>

- [Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets](#)
Pharma Live: Nov 2 2009 9:49PM Matching: laboratoires
- [Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets](#)
SmartBrief: Oct 31 2009 2:00AM Matching: laboratoires
- [Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets](#)
Pharmacy Choice: Oct 30 2009 10:34PM Matching: laboratoires
- [Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets](#)
Genetic Engineering News: Oct 30 2009 3:57PM Matching: laboratoires
- [Impax Laboratories Confirms Patent Challenge Relating to TRICOR 48mg and 145mg Tablets](#)
Yahoo! Canada: Oct 30 2009 3:51PM Matching: laboratoires
- [Impax Laboratories initiates patent challenge for TRICOR](#)
News-Medical.Net: Oct 30 2009 3:27PM Matching: laboratoires
- [Impax Laboratories \(IPXL\) Initiates Challenges to Abbott's Patents in Connection to TRICOR](#)
Street Insider: Oct 30 2009 2:53PM Matching: laboratoires
- [FDA Approves Ophthalmic Gel for Herpes Keratitis](#)
Cataract & Refractive Surgery Today: Oct 25 2009 5:16PM Matching: laboratoires
- [FDA Approves Ophthalmic Gel for Herpes Keratitis](#)
CRS Today: Oct 23 2009 5:37PM Matching: laboratoires
- [Laboratoires Paladin et Pfizer modifient l'accord canadien portant sur Estring\(MD\)](#)
NewsBlaze: Oct 15 2009 10:49PM Matching: laboratoires
- [Paladin obtient les droits canadiens sur une thrapie l'estrogne de Pfizer](#)
Metro Montreal: Oct 15 2009 8:47PM Matching: laboratoires
- [ResMed adds Laboratoires Narval to respiratory offering](#)
Clinica: Oct 13 2009 3:45PM Matching: laboratoires
- [FDA approves Sirion's NDA for ganciclovir 0.15% for herpetic keratitis](#)
Modern Medicine: Oct 8 2009 4:02PM Matching: laboratoires
- [ResMed buys French device firm for about \\$12M](#)
SmartBrief: Oct 7 2009 11:14PM Matching: laboratoires
- [EU raids drug makers Sanofi-Aventis, Sandoz and Ratiopharm on suspected antitrust abuse](#)
San Francisco Examiner: Oct 7 2009 3:21PM Matching: laboratoires

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast

service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

